<DOC>
	<DOCNO>NCT01953822</DOCNO>
	<brief_summary>This observational cohort study ass risk autoimmune disease ( ) within 12 month receive first dose Cervarix® expose cohort comparable period unexposed cohort . This alternative study GSK use CPRD database UK fulfil US FDA safety commitment . The UK sufficient Cervarix® vaccination coverage period mid-September 2008 2011 allow suitable data collect .</brief_summary>
	<brief_title>Study Assessing Risk Autoimmune Diseases Females ( 9 - 25 Years ) Exposed Cervarix® United Kingdom</brief_title>
	<detailed_description>GSK 's vaccine Cervarix® protect Human Papilloma Virus Types-16 18-related pre-cancerous lesion . GSK commit US Food Drug Administration ( FDA ) conduct safety study evaluate incidence new neurological eye-related autoimmune diseases pre-specified autoimmune disease subject receive Cervarix® US . Because low Cervarix® uptake US , observational GSK study address commitment due stop , take long recruit target subject . The unexposed male cohort enrol order ass possible change time incidence rate new onset autoimmune disease ( ) ( NOAD ) UK Clinical Practice Research Datalink General Practitioner OnLine database ( CPRD GOLD ) independent Cervarix® introduction . The cohort frequency match age ( age class one year ) practice region identifier reference date ( age first dose Cervarix ) . Additionally , reference date ( time = 0 ) vaccinate ( expose ) cohort date first dose Cervarix® record CPRD GOLD . The reference date unexposed ( unvaccinated ) cohort date randomly select among reference date expose subject minus 3 year historical cohort . The observational study model self-control case-series ( SCCS ) analysis confirm NOAD expose female cohort , use risk period one year first Cervarix® dose , control period one year six month buffer period risk control period . Human Papillomavirus Bivalent ( Types 16 18 ) vaccine ( recombinant ) expose cohort investigate 1-SEP-2008 31-AUG-2010 . The unexposed concurrent male cohort investigate 1-SEP-2008 31-AUG-2010 . Unexposed historical female male cohort investigate 1-SEP-2005 31-AUG-2007 .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>Note : Other vaccine allow study regardless time administration time interval subsequent dos . Inclusion criterion expose female cohort : Female age 9 25 year reference date ( 01 September 2008 31 August 2010 ) . Recorded CPRD GOLD least 12 month reference date . The first dose Cervarix receive 01 September 2008 31 August 2010 , Full date ( day/month/year ) Cervarix vaccination ( ) available . Subject define acceptable CPRD GOLD . Inclusion criterion unexposed historical female cohort : Female age 9 25 year reference date ( 01 September 2005 31 August 2007 ) . Recorded CPRD GOLD least 12 month reference date . Subject define acceptable CPRD GOLD . Inclusion criterion unexposed concurrent male cohort : Male age 9 25 year reference date ( 01 September 2008 31 August 2010 ) . Recorded CPRD GOLD least 12 month reference date . Subject define acceptable CPRD GOLD . Inclusion criterion unexposed historical male cohort : Male age 9 25 year reference date ( 01 September 2005 31 August 2007 ) . Recorded CPRD GOLD least 12 month reference date . Subject define acceptable CPRD GOLD . Exclusion criterion cohort : Subjects diagnostic code autoimmune disease year prior reference date . Subjects receive least one dose unspecified HPV vaccine Gardasil time reference date . Subjects include cohort . Exclusion criterion nonexposed cohort : • Subjects receive dose Cervarix time reference date .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Observational</keyword>
	<keyword>Cohort</keyword>
	<keyword>Autoimmune disease</keyword>
	<keyword>Cervarix®</keyword>
	<keyword>Women age 9 25 year</keyword>
	<keyword>United Kingdom</keyword>
</DOC>